News Breaks |
|
|
| December 27, 2012 |
| 08:21 EDT |  | RHHBY, VVUS, ARNA, OREX, GSK | U.S. market gets wave of new weight loss drugs, FT reports
The U.S. market has had only one prescription weight loss drug for several years, Roche’s (RHHBY) Xenical, which is also sold over-the-counter by GlaxoSmithKline (GSK) as Alli, but that drug has recently been joined by Vivus' (VVUS) Qsymia and Arena (ARNA) is set to launch Belviq shortly, reported Financial Times. Orexigen (OREX) is also preparing to re-submit its Contrave weight loss drug for a new regulatory review. The report on the resurgence of weight loss drug development noted that Vivus' CEO foresees the potential for using direct-to-consumer advertising and a larger scale sales force to market Qsymia, which would likely require a big pharma partner. Reference Link |
|
|
News For VVUS;ARNA;OREX;GSK;RHHBY From The Last 14 Days Check below for free stories on VVUS;ARNA;OREX;GSK;RHHBY the last two weeks. |
|
|
| May 17, 2013 |
| 11:53 EDT |  | ARNA | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 15, 2013 |
| 15:59 EDT | | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 14:03 EDT |  | ARNA | Arena Pharma has positive read through from Eisai forecast, says Piper Jaffray
Subscribe for More Information |
|
| 12:13 EDT |  | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT |  | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 06:19 EDT | | ARNA | Arena Pharmaceuticals implied volatility at lower end of index mean range
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| 10:01 EDT |  | VVUS | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 07:33 EDT | | VVUS | VIVUS downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information |
|
| 07:24 EDT | | GSK | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
| |
| May 13, 2013 |
| 16:25 EDT |  | GSK | On The Fly: Closing Wrap
Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. |
|
| 12:20 EDT | | GSK | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 08:55 EDT | | RHHBY | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| 07:41 EDT | | VVUS | VIVUS mails letter to stockholders providing business update
Subscribe for More Information |
|
| 07:30 EDT | | RHHBY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| 05:44 EDT | | GSK | Elan provides additional information on Elan/Theravance agreement
Subscribe for More Information |
|
| 05:35 EDT | | GSK | Theravance, Elan enter into $1B royalty participation agreement
Subscribe for More Information |
|
| May 10, 2013 |
| 15:59 EDT | | RHHBY | Roche spokesman reiterates that Illumina is "off the table," Bloomberg reports
Subscribe for More Information |
|
| 12:42 EDT | | GSK | GlaxoSmithKline, Theravance confirm FDA approval of Breo Ellipta
Subscribe for More Information |
|
| 11:48 EDT | | RHHBY, GSK | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
| |
|
|
|
|
